Terms: = Gastric cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
17 results:
1. A degradome-related signature for predicting the prognosis and immunotherapy benefit in stomach adenocarcinoma based on machine learning procedure.
Deng Z; Feng Q; Zhao D; Huang Z
Medicine (Baltimore); 2024 Apr; 103(15):e37728. PubMed ID: 38608069
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcome and molecular landscape of patients with ARID1A-loss gastric cancer.
Sun M; Gu Y; Fang H; Shao F; Lin C; Zhang H; Li H; He H; Li R; Wang J; Liu H; Xu J
Cancer Sci; 2024 Mar; 115(3):905-915. PubMed ID: 38148578
[TBL] [Abstract] [Full Text] [Related]
3. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
4. Identifying immune cells-related phenotype to predict immunotherapy and clinical outcome in gastric cancer.
Jiang S; Ding X; Wu Q; Cheng T; Xu M; Huang J
Front Immunol; 2022; 13():980986. PubMed ID: 36032097
[TBL] [Abstract] [Full Text] [Related]
5. Distribution, phenotype, functional and clinical relevance of CD8
Shen Y; Li XL; Li YX; Shan ZG; Zhao YL; Cheng P; Zhao Z; Zhang JY; Chen W; Zhuang Y; Ma DY; Zou QM; Qiu Y; Peng LS
Cancer Immunol Immunother; 2022 Jul; 71(7):1645-1654. PubMed ID: 34767045
[TBL] [Abstract] [Full Text] [Related]
6. Pyroptosis Patterns Characterized by Distinct Tumor Microenvironment Infiltration Landscapes in gastric cancer.
Xiang R; Ge Y; Song W; Ren J; Kong C; Fu T
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680930
[TBL] [Abstract] [Full Text] [Related]
7. The crosstalk between H. pylori virulence factors and the pd1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract] [Full Text] [Related]
8. Determinants of Response and Intrinsic Resistance to pd-1 Blockade in Microsatellite Instability-High gastric cancer.
Kwon M; An M; Klempner SJ; Lee H; Kim KM; Sa JK; Cho HJ; Hong JY; Lee T; Min YW; Kim TJ; Min BH; Park WY; Kang WK; Kim KT; Kim ST; Lee J
Cancer Discov; 2021 Sep; 11(9):2168-2185. PubMed ID: 33846173
[TBL] [Abstract] [Full Text] [Related]
9. Cytolytic activity score as a biomarker for antitumor immunity and clinical outcome in patients with gastric cancer.
Hu Q; Nonaka K; Wakiyama H; Miyashita Y; Fujimoto Y; Jogo T; Hokonohara K; Nakanishi R; Hisamatsu Y; Ando K; Kimura Y; Masuda T; Oki E; Mimori K; Oda Y; Mori M
Cancer Med; 2021 May; 10(9):3129-3138. PubMed ID: 33769705
[TBL] [Abstract] [Full Text] [Related]
10. Immune Profile Analysis in Peripheral Blood and Tumor in Patients with Malignant Melanoma.
Saito R; Sawada Y; Nakamura M
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669410
[TBL] [Abstract] [Full Text] [Related]
11. Better prognosis of gastric cancer patients with high levels of tumor infiltrating lymphocytes is counteracted by pd-1 expression.
Pötzsch M; Berg E; Hummel M; Stein U; von Winterfeld M; Jöhrens K; Rau B; Daum S; Treese C
Oncoimmunology; 2020 Sep; 9(1):1824632. PubMed ID: 33101772
[TBL] [Abstract] [Full Text] [Related]
12. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report.
Merhi M; Raza A; Inchakalody VP; Siveen KS; Kumar D; Sahir F; Mestiri S; Hydrose S; Allahverdi N; Jalis M; Relecom A; Al Zaidan L; Hamid MSE; Mostafa M; Gul ARZ; Uddin S; Al Homsi M; Dermime S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32913031
[TBL] [Abstract] [Full Text] [Related]
13. Microsatellite instability status differentially associates with intratumoral immune microenvironment in human cancers.
Zhang P; Liu M; Cui Y; Zheng P; Liu Y
Brief Bioinform; 2021 May; 22(3):. PubMed ID: 32823273
[TBL] [Abstract] [Full Text] [Related]
14. Anti-pd-1/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis.
Park R; Lopes L; Saeed A
Clin Transl Oncol; 2021 Jan; 23(1):100-109. PubMed ID: 32495269
[TBL] [Abstract] [Full Text] [Related]
15. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from gastric cancer Patients.
Ito S; Fukagawa T; Noda M; Hu Q; Nambara S; Shimizu D; Kuroda Y; Eguchi H; Masuda T; Sato T; Katai H; Sasako M; Mimori K
Ann Surg Oncol; 2018 Nov; 25(12):3755-3763. PubMed ID: 30203407
[TBL] [Abstract] [Full Text] [Related]
17. A Four-Factor Immunoscore System That Predicts clinical outcome for Stage II/III gastric cancer.
Wen T; Wang Z; Li Y; Li Z; Che X; Fan Y; Wang S; Qu J; Yang X; Hou K; Zhou W; Xu L; Li C; Wang J; Liu J; Chen L; Zhang J; Qu X; Liu Y
Cancer Immunol Res; 2017 Jul; 5(7):524-534. PubMed ID: 28619967
[TBL] [Abstract] [Full Text] [Related]
